Sildenafil - N4 Pharma
Alternative Names: N4S001Latest Information Update: 02 Oct 2021
At a glance
- Originator N4 Pharma
- Developer Bio-Images Drug Delivery; N4 Pharma
- Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Erectile dysfunction
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Erectile-dysfunction(In volunteers) in United Kingdom (PO, Tablet)
- 13 Jun 2018 N4 Pharma and BDD Pharma completes a phase I trial in Erectile dysfunction (In volunteers) in United Kingdom (NCT03510338)
- 05 Jun 2018 Chemical structure information added